Globe Life GL Q4 2025 Earnings Call Transcript

Globe Life reported Q4 net operating income of $274 million, or $3.39 per share, up 8%, with full-year 2025 net operating EPS of $14.52 and book value per share including AOCI up 11% to $96.16. Management raised 2026 guidance for total premium revenue to 7%-8% growth and EPS to $14.95-$15.65, while maintaining a 300%-320% RBC target and signaling continued buybacks of $535 million to $585 million. Health growth is accelerating on Medicare Supplement demand and rate increases, though margins are expected to remain below life due to mix and claims pressure.

Analysis

GL’s setup is less about top-line growth and more about capital intensity falling just enough to keep buybacks compounding while earnings stay resilient. The hidden lever is mix: faster growth in lower-margin Medicare Supplement is a near-term drag on reported health margin percentage, but it expands underwriting dollars and frees more capital per unit of premium than the limited-benefit lines, which should support a higher repurchase run-rate into 2026.

The more important second-order effect is that the Bermuda reinsurance platform is an option, not part of the base case. If regulators eventually allow faster dividend upstreaming, GL could move from a steady buyback story to a materially larger capital return story, but that inflection is unlikely to show up in the next few quarters. In the meantime, the market may underappreciate how much of the 2026 EPS path is driven by actuarial/experience tailwinds rather than pure volume, which makes the midpoint less durable if mortality or lapse trends normalize.

The main risk is not underwriting disaster; it is a stumble in distribution efficiency. Higher lapses in DTC and Liberty National suggest the company is having to spend more to keep the sales engine turning, and that usually shows up with a lag in retention economics before it shows up in headline premium growth. A second risk is that health margin upside is back-end loaded: Q1 likely looks softer, so the stock can easily de-rate on a temporary miss before rate increases flow through. That creates a tactically interesting entry point rather than an all-clear signal.

Contrarian read: consensus will likely focus on the 5% EPS guide and miss that normalized EPS growth is closer to double-digit once assumption resets are stripped out. If management executes on retention and gets even partial Bermuda cash release optionality, the market could be forced to rerate GL as a capital-return compounder rather than a slow-growth insurer. Conversely, if Medicare Supplement demand cools or pricing discipline erodes, the valuation support weakens quickly because much of the bull case is predicated on monetizing today’s strong cycle rather than building a new one.

Key Decisions for Investors

• Long GL on any post-earnings pullback over the next 2-6 weeks; target a 10%-15% rebound as the market digests normalized EPS growth and buyback support. Risk: Q1 health margin softness or lapse headlines can pressure the stock before the rate increases flow through.
• Pair trade: long GL / short a higher-quality growth insurer with less capital return optionality for 3-6 months. Thesis: GL’s underappreciated buyback intensity and actuarial tailwinds should outperform peers whose earnings growth is more purely operational.
• Buy GL July/Sept 2026 calls on weakness to express the Q3 assumption-update catalyst. Risk/reward is favorable because the market can reprice the stock on a discrete remeasurement gain and associated margin step-up.
• If already long, add on confirmation that retention initiatives stabilize DTC and Liberty National lapses over the next two quarters. A sustained lapse improvement is the cleanest signal that sales productivity gains are durable rather than cyclical.
• Avoid chasing the stock immediately if it trades up on the headline guide; wait for the first-quarter digestion period, when seasonally weaker health margins and higher lapse scrutiny are most likely to create a better entry.